SCHEMBL22353042

SCHEMBL22353042

C=C(C)C(=O)Oc1ccc(-c2ccc3c(c2)C(=C)c2cc(-c4ccc(OC(=O)C(=C)C)cc4)ccc2-3)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.48
KMT2A Q03164 2/20 0.44
ATM Q13315 1/20 0.44
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.38
MAPT P10636 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
BACE1 P56817 1/20 0.36
HPGD P15428 1/20 0.33
POLB P06746 1/20 0.33
GAPDH P04406 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GFER P55789 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NR1H2 P55055 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22353041 0.97 ELANE (0.46) ELANEKMT2AATMLMNAGAA
SCHEMBL24377891 0.91 ELANE (0.44) ELANEKMT2AATMLMNAGAA
SCHEMBL22345623 0.87 ELANE (0.49) ELANEKMT2AATMLMNAMAPT
SCHEMBL22352935 0.87 ELANE (0.41) ELANEKMT2AATMMAPTBACE1
SCHEMBL22353033 0.86 ELANE (0.40) ELANEKMT2AATMMAPTBACE1
SCHEMBL22352922 0.85 ELANE (0.40) ELANEKMT2AATMCYP2C19
SCHEMBL22353031 0.84 CFD (0.40) ELANEKMT2AATMGAAMAPT
SCHEMBL22352923 0.84 ELANE (0.39) ELANEKMT2AATMHSD17B10TDP1
SCHEMBL17433304 0.83 ELANE (0.62) ELANEKMT2AATMLMNAGAA
SCHEMBL803168 0.83 ELANE (0.62) ELANEKMT2AATMLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3924447-B1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2024-01-24 EP disclosed
US-11685863-B2 Polymerisable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2023-06-27 US disclosed
US-20220127532-A1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2022-04-28 US disclosed
WO-2020165394-A1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2020-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127532-A1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS LPXN, VCL, LCP1 ELANE 1153/4885KMT2A 2566/4885ATM 1563/4885
US-11685863-B2 Polymerisable compounds and the use thereof in liquid-crystal displays LPXN, VCL, LCP1 ELANE 1153/4885KMT2A 2566/4885ATM 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.